

[France Accueil](#)

20030-U - ORBO™ 502 Activated Silica Gel (20/45) 100/50 mg




20030-U Supelco

ORBO™ 502 Activated Silica Gel (20/45) 100/50 mg

W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea

Synonym: ORBO™ Activated Silica Gel Tube



[FDS](#)[Similar Products](#)

Conditionnement - SKU	Disponibilité	Prix (EUR)	Quantité
20030-U	Seulement 6 en stock (d'autres en cours d'arrivage) - A PARTIR DE	200.00	<input type="text" value="0"/>

Commandes Bulk?

AJOUTER AU PANIER

Propriétés

Related Categories	Active Sampling, Air Monitoring, Analytical/Chromatography, ORBO Sorbent Tubes For Gas & Vapor Sampling, Sample Preparation & Purification, Silica Gel Sorbent Tubes, Solvent Desorption Tubes & Cartridges Less...
material	W,W,F separators
composition	Bed A, 100 mg Bed B, 50 mg
packaging	pkg of 50 ea
mfr. no.	ORBO™ 502
O.D. × L	6 mm × 75 mm
matrix	activated silica gel
particle size	20-45 mesh
Agency/Method	NIOSH 2000 NIOSH 5518

[montrer moins de résultats](#)

Description

Legal Information
ORBO is a trademark of Sigma-Aldrich Co. LLC

Informations Sécurité

RIDADR	NONH for all modes of transport
WGK Germany	3

Documents

Certificat d'Analyse

ORB00061



[Devis/ Commande de produits Bulk](#)

[FDS](#)

Customers Also Viewed

 20032 ORBO™ 506 Activated Silica Gel (45/60) 300/150 mg W,W,W separators, O.D. × L 8 mm × 75 mm, pkg of 50 ea	 20229 ORBO™ 52 Small Activated Silica Gel (20/40) 150/75 mg, pk 50 W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea	20870-U ORBO™ 507 Silica Gel (20/40), 520/260 mg W,W,F separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea	 20265 ORBO™ 53 Activated Silica Gel (20/40) specially cleaned, 400/200 mg with Glass Fiber Filters GFF,F,F separators, O.D. × L 7 mm × 100 mm, pkg of 50 ea	 20263 ORBO™ 52 Large Activated Silica Gel (45/60) 150/150 mg W,W,W separators, O.D. × L 8 mm × 75 mm, pkg of 50 ea
--	---	---	---	---

Recently Viewed

 20029-U ORBO™ 65P (OVS) Amberlite® XAD®-4 specially cleaned, 160/80 mg RC,GFF,F,F (specially cleaned) separators, O.D. × L 13 to 8 mm × 75 mm	 20019-U ORBO™ 303 Activated Petroleum Charcoal (20/40), 100/50 mg W,F,F separators, O.D. × L 6 mm × 70 mm, pkg of 50 ea	58820 Sample Rotor for Model 7520 Microsample Injector size 0.2 µL	58805 Needle Insert for Dressing Tool configured for 1/16 in.	58804 Deburring Tool configured for 1/16 in. tubing
--	--	--	---	---

Protocoles et articles

Documentation référencée

Did you use this product in your Paper? If so click here.

[read abstract](#)

Trapping efficiency of selected adsorbents for various airborne pesticides.
R B Leidy and C G Wright
Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes, 26(4), undefined (1991-8-1)
A study was conducted to compare the efficiency of five adsorbents used by government and private laboratories to collect airborne pesticides. Six pesticides, acephate, chlordane, chlorpyrifos, diazinon, heptachlor, and propoxur, were vaporized in a ...[Read More](#)

[read abstract](#)

The oxidation of toluene sorbed on activated carbon in the presence of H(2)O(2) and manganese oxide.
Si-Hyun Do and Sung-Ho Kong
Water science and technology : a journal of the International Association on Water Pollution Research, 66(11), undefined (2012-10-4)
We investigated the oxidation of toluene sorbed on activated carbon (AC) in the presence of hydrogen peroxide (H(2)O(2)) and pyrolusite (MnO(2)). Sorbed toluene was prepared by reacting a toluene-saturated solution and AC. The amounts of sorbed toluene...[Read More](#)

[read abstract](#)

Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
Marit Arnes et. al
Anticancer research, 34(5), undefined (2014-4-30)
The main objective was to investigate if occurrence of hyperplastic polyps was reduced by use of the levonorgestrel-impregnated intrauterine system (LNG-IUS, Mirena®; Bayer) and if the LNG-IUS was more effective compared to oral medroxyprogesterone a...[Read More](#)

[read abstract](#)

Increased gene expression of the ABCC5 transporter without distinct changes in the expression of PDE5 in human cervical cancer cells during growth.
Tormod Eggen et. al
Anticancer research, 32(8), undefined (2012-7-31)
Carcinoma of the uterine cervix represents the second most frequent female malignancy worldwide, but few biochemical tumour markers have been implemented into clinical practice. Elevated extracellular guanosine 3', 5'-cyclic monophosphate (cGMP) leve...[Read More](#)

[read abstract](#)

Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
Anne Ørbo et. al
Anticancer research, 35(12), undefined (2015-12-8)
To investigate if a levonorgestrel-impregnated intrauterine system (LNG-IUS) was more efficient compared to oral progestin in the clearance of the paired box 2 gene (PAX2) - and phosphatase and tensin homolog (PTEN)-null endometrial glands and assess...[Read More](#)

[read abstract](#)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
Anne Ørbo et. al
British journal of cancer, 115(6), undefined (2016-8-19)
The aim of the present study was to investigate whether changes in the tissue expression of human epididymis-specific protein 4 (HE4) could predict therapy resistance and relapse after progestin hormone therapy for medium- and low-risk endometrial hy...[Read More](#)

[read abstract](#)

Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
Elise Thoresen Sletten et. al
Anticancer research, 37(5), undefined (2017-5-10)
To investigate whether risk of relapse of endometrial hyperplasia persists many years after successful primary therapy and whether clinical or biological markers observed at primary diagnosis may predict relapse. A series of 57 women with endometrial...[Read More](#)

[read abstract](#)

Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
A Ørbo et. al
BJOG : an international journal of obstetrics and gynaecology, 123(9), undefined (2015-12-3)
To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena®) or two regimens of oral medroxyprog...[Read More](#)

[read abstract](#)

Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy.

Bjørn T Moe et. al

Anticancer research, 29(4), undefined (2009-5-6)

Endometrial hyperplasia is a precursor lesion of endometrial carcinoma. Clinical studies of endometrial hyperplasia have shown that levonorgestrel (LNG) is more therapeutically effective than medroxyprogesterone acetate (MPA). The present pharmacolog...[Read More](#)

[read abstract](#)

Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.

Anne Beate Vereide et. al

Gynecologic oncology, 97(3), undefined (2005-5-12)

The aim of the study was to investigate apoptosis as a growth regulatory mechanism of gestagen in endometrial precancers and to compare differences in the apoptotic cascade after high and low dose gestagen regimens. Pre- and post-treatment paraffin-e...[Read More](#)

[read abstract](#)

[How hazardous is the use of female steroid hormones?].

A Orbo and G Sager

Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række, 117(7), undefined (1997-3-10)

The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancer...[Read More](#)

[read abstract](#)

Effect of probenecid, verapamil and progesterone on the concentration-dependent and temperature-sensitive human erythrocyte uptake and export of guanosine 3',5' cyclic monophosphate (cGMP).

K Flo et. al

Scandinavian journal of clinical and laboratory investigation, 55(8), undefined (1995-12-1)

Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiology...[Read More](#)

[read abstract](#)

Early effects of high concentrations of progesterone and mifepristone A gene expression study of endometrial cancer cells (Ishikawa).

Anne Ørbo et. al

The Journal of steroid biochemistry and molecular biology, 113(1-2), undefined (2009-1-14)

Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been...[Read More](#)

[read abstract](#)

Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia.

A Orbo et. al

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 22(2), undefined (2003-3-22)

Derangements in the tumor suppressor gene PTEN and the mismatch-repair genes, hMLH1, hMSH2, and hMSH6, have an important role in endometrial carcinogenesis. The purpose of this study was to assess immunohistochemically the pattern of protein expressi...[Read More](#)

[read abstract](#)

Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias.

J P Baak et. al

The American journal of surgical pathology, 25(7), undefined (2001-6-23)

Prospective multicenter evaluation of the WHO classification and the morphometric D-score to predict endometrial hyperplasia cancer progression. In 132 endometrial hyperplasias WHO classification was performed by two experienced gynecologic pathologi...[Read More](#)

[Show more references \(54 remain\)](#)

Produits associés



Milli-o® water purification solutions

Ultrapure & Pure Systems for Every Lab

[Learn More](#)

© 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Reproduction of any materials from the site is strictly forbidden without permission. Sigma-Aldrich Products are sold exclusively through Sigma-Aldrich, Inc. [Site Use](#) [Terms](#) | [Privacy](#)